A Comprehensive Proteomic Analysis of Tuberculosis Glycoprotein Antigens as Emerging Biomarkers for Active Disease Diagnosis
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Alireza Hadizadeh Tasbiti1,2, Shamsi Yari1,2, Seyed Davar Siadat1,2, Abolfazl Fateh1,2, Morteza Maomi1,2, Maryam Karbasian1,2, Farid Abdolrahimi1,2 1Department of Tuberculosis and Pulmonary Research, Pasteur Institute of Iran, 2Microbiology Research Center, Pasteur Institute of Iran, Tehran, Iran Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs. Traditionally, TB diagnosis relies on smear microscopy and Mycobacterial culture. However, microscopy has limited sensitivity, often failing to detect smear-negative TB, and results typically take up to 2 months. In high-income countries, enhanced diagnostic methods such as molecular tests have been developed, but these options are frequently too expensive and complex for routine application in resource-constrained settings where TB is prevalent. Accurate, rapid, cost-effective, and straightforward diagnostic tests are urgently needed for effective TB care and control. In this study, significant efforts have been made to create a rapid TB test centered on Mycobacterium antigen detection. However, our primary goal is to develop a rapid TB antigen detection test utilizing glycoprotein biomarkers. Previous research has focused on identifying host responses related to TB infection. Our approach utilizes the competitive enzyme-linked immunosorbent assay technique to recognize TB antigens. We purified at least 200 glycoproteins through Concanavalin A affinity chromatography and subsequently identified them using Liquid chromatography Mass spectrometry. To analyze posttranslational modifications, we utilized the GlycoPP web server to predict potential N- and O-glycosylation sites within the TB protein sequences. Furthermore, these proteins were assessed using the Immune Epitope Database (IEDB) and B-cell epitope prediction tools to identify linear epitopes from their protein sequences. Sputum samples were collected from patients suspected of having TB. Among these individuals, 54% were confirmed to have TB, while 46% were diagnosed with non-TB conditions. The purified glycoproteins included Rv3873, Rv0934, Rv1078, Rv0954, Rv0173, Rv0583c, Rv1270c, Rv1543, Rv0341, Rv1860, Rv2560, Rv0174, and Rv0838. Notably, Rv0954, Rv1078, Rv0838, Rv0583c, and Rv1860 displayed high compatibility scores (>70%). Receiver operating characteristic curve analysis was performed to determine the optimal cutoff value (≤0.55) for differentiating between TB and non-TB groups. The assay demonstrated a sensitivity of 91.15% and a specificity of 94.24%. These findings highlight the diagnostic potential of the identified glycoprotein biomarkers for TB. Keywords: Immune Epitope Database and B-cell epitope prediction, mass spectrometry, tuberculosis antigen detection, tuberculosis glycoproteins Conflicts of interest There are no conflicts of interest
Fields of Study & Subjects
Tuberculosis Research and Epidemiology
Glycosylation and Glycoproteins Research
Infectious Diseases and Tuberculosis
Publication details
- Journal / source
- International Journal of Mycobacteriology
- Volume
- 15
- Issue
- Abstract Supplement
- Pages
- S27–S27
- Publication date
- 1 March 2026
- Language
- EN